trending Market Intelligence /marketintelligence/en/news-insights/trending/i7cVfk56s79BLTXD1J7u2g2 content esgSubNav
In This List

J&J to bolster global efforts with $500M investment to combat HIV, tuberculosis

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


J&J to bolster global efforts with $500M investment to combat HIV, tuberculosis

Johnson & Johnson is committing about $500 million in research and development over four years to help global efforts to eliminate HIV and tuberculosis by 2030.

The New Brunswick, N.J.-based pharmaceutical giant said it will dedicate researchers to accelerate the development of next-generation medicines and vaccines to complement investments being made by governments.

As part of the $500 million investment, Johnson & Johnson's unit Janssen Pharmaceutical Cos. will continue to advance an investigational mosaic-based vaccine regimen to prevent HIV, along with a consortium of partners.

Johnson & Johnson and ViiV Healthcare Ltd., which is majority-owned by GlaxoSmithKline PLC, are already evaluating a two-drug regimen for HIV that has been shown to be as effective as an injection administered every two months.

Around 37 million people are living with HIV globally.

The company added that in September 2018, it had announced a 10-year initiative to support efforts for ending the tuberculosis epidemic by 2030. Johnson & Johnson said it was working with partners to improve the detection of undiagnosed cases of tuberculosis and help in discovering next-generation therapies for the disease.